NCT03801434进行中（未招募）2 期
Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 8
- 试验地点
- 8
- 主要终点
- Overall response rate (ORR)
研究概览
简要总结
This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.
详细描述
PRIMARY OBJECTIVES:
I. To determine the overall hematologic response rate to ruxolitinib in patients with hypereosinophilic syndrome and primary eosinophilic disorders.
SECONDARY OBJECTIVES:
I. To determine safety profile of ruxolitinib in patients with hypereosinophilic syndrome and primary eosinophilic disorders.
II. To determine the proportion of patients on corticosteroids who are able to become corticosteroid-independent and/or reduce the dose by >= 50%.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject with idiopathic hypereosinophilic syndrome must meet the following:
- •Has as at least 2 readings with an absolute eosinophil count >= 1,500/mm^3 in the preceding 3 months prior to starting ruxolitinib (one reading must be during the screening period).
- •Dependent, intolerant or refractory to corticosteroids OR has relapsed/refractory disease to other therapy besides corticosteroids.
- •Symptomatic from his/her disease OR has one or more signs of organ damage (assessed by the investigator as possibly-related to eosinophilia or biopsy-proven). This can include skin, lung, cardiac, central nervous system, liver, or gastrointestinal (GI) involvement, or evidence of symptomatic hepatic or splenic enlargement.
- •Subject with lymphocyte-variant hypereosinophilia must meet the following
- •Has at least 2 readings with an absolute eosinophil count >= 1,500/mm^3 in the preceding 3 months prior to starting ruxolitinib (one reading must be during the screening period).
- •Dependent, intolerant or refractory to corticosteroids* OR has relapsed/refractory disease to other therapy besides corticosteroids.
- •Symptomatic from his/her disease OR has one or more signs of organ damage (assessed by the investigator as possibly-related to eosinophilia or biopsy-proven). This can include skin, lung, cardiac, central nervous system, liver, or GI involvement, or evidence of symptomatic hepatic or splenic enlargement
- •Has abnormal T-lymphocyte immuno-phenotype by flow cytometry.
- •Subject with chronic eosinophilic leukemia, not otherwise specified (CEL,NOS) must meet the following
- •Has at least 2 readings with an absolute eosinophil count >= 500/mm^3 in the preceding 3 months prior to starting ruxolitinib (one reading must be during the screening period).
- •Newly-diagnosed OR receiving corticosteroids OR has relapsed/refractory disease to any therapy besides corticosteroids.
- •Has increased blasts in the blood or bone marrow (> 5% and < 20%), and/or a clonal cytogenetic or molecular abnormality
- •Subjects with JAK2 mutations are included within this group.
- •Subject with JAK2-rearranged eosinophilic neoplasm must meet the following
- •Has at least 2 readings with an absolute eosinophil count >= 500/mm^3 in the preceding 3 months prior to starting ruxolitinib (one reading must be during the screening period).
- •Newly-diagnosed OR receiving corticosteroids OR has relapsed/refractory disease to any therapy besides corticosteroids.
- •This group includes subjects with PCM1-JAK2, BCR-JAK2, ETV6-JAK2 or other JAK2 rearrangements.
- •If receiving corticosteroids, must be a stable dose for >= 28 days prior to Day 1 (unstable dosing not eligible).
- •Eastern Cooperative Oncology Group (ECOG) performance status =<
- •Willing and able to review and execute informed consent (legally-authorized consent acceptable).
排除标准
- •Active life-threatening complication(s) from underlying eosinophilic disease (i.e., leukostasis; acute thromboembolic disease including central nervous system (CNS) involvement; severe pulmonary or cardiac dysfunction). Stabilization of acute, life-threatening eosinophil-related co-morbidities will allow enrollment of the patient.
- •World Health Organization (WHO)-defined myeloid neoplasm associated with eosinophilia other than CEL NOS and JAK2 rearranged neoplasms (e.g., myelodysplastic syndrome (MDS); myeloproliferative neoplasms (MPN); MDS/MPN overlap disorders; and systemic mastocytosis (SM).
- •Reactive hypereosinophilia due to connective tissue disease, sarcoidosis or eosinophilic granulomatosis with polyangiitis.
- •Organ-restricted ?tissue? eosinophilia with the absence of peripheral eosinophilia in the blood.
- •Invasive malignancy over the previous 2 years except treated early stage carcinomas of the skin, completely resected intraepithelial carcinoma of the cervix, and completely resected papillary thyroid and follicular thyroid cancers.
- •Myeloid or lymphoid neoplasm with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR
- •Anticipated to receive a hematopoietic stem cell transplant within the first 6 months of treatment on trial.
- •Major surgery within 4 weeks prior to entering the study.
- •Life expectancy of < 6 months.
- •Known diagnosis of human immunodeficiency virus (HIV).
- •Known diagnosis of chronic active hepatitis B or C (viral testing is not required). Subjects with a known history of hepatitis B and/or C are allowed on trial if at the time of enrollment, the virus is not active and undetected (testing required if there is a known history), and such patients are not actively receiving antiviral treatment specific for hepatitis B and/or C.
- •Clinically serious infections requiring ongoing antibiotic therapy.
- •Parasitic infection diagnosed within 24 weeks prior to enrollment.
- •Platelet count =< 25 x 10^9/L at baseline.
- •Alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) > 4 x upper limit of normal (ULN) or direct bilirubin > 4 x ULN (if considered to be unrelated to the underlying eosinophilic disorder).
- •End-stage renal function (creatinine clearance [CrCl] < 15 mL/min or glomerular filtration rate [GFR] < 15 mL/min) regardless of whether hemodialysis is required.
- •Use of investigational or commercial therapies with the intent to treat the underlying eosinophilic disorder within 28 days of study start, including interferon; imatinib; alemtuzumab; cyclosporine; methotrexate; mepolizumab; benralizumab; or other antibody therapies.
- •Use of hydroxyurea within 7 days of study start.
- •Prior therapy with ruxolitinib or other JAK inhibitors.
- •Previous allergic reactions to JAK inhibitors or excipients.
- •Unwilling to commit to abstinence from heterosexual contact or agree to use and comply with highly effective contraception, 28 days prior to starting study drug, during the treatment period and for 12 weeks after discontinuation of study treatment.
- •Females of childbearing potential who have a positive pregnancy test (urine or serum) during screening period.
研究组 & 干预措施
Treatment (ruxolitinib)
Experimental
Patients receive ruxolitinib PO BID on days 1-28. Treatment repeats for up to 6 cycles (28 days each) in the absence of disease progression or unacceptable toxicity.
干预措施: Ruxolitinib (Drug)
结局指标
主要结局
Overall response rate (ORR)
时间窗: 3 years
ORR is the sum of complete response (CR) plus complete response with incomplete platelet recovery (CRp) plus partial response (PR). Complete response, with platelet incomplete platelet recovery (CRp) is defined as a response that meets CR criteria but platelet count remains below 100 x 10\^9/L. This outcome will be reported as a number. * Complete response (CR) = normalization of white blood cell (WBC) count; absolute eosinophil count in blood; and % eosinophils in blood, without increased blasts or eosinophils in bone marrow, and with a non-palpable spleen and/ or normal spleen size by imaging. * Partial response (PR) is defined as ≥ 50% reduction (if above normal range) in all the following: total WBC count; absolute eosinophil count in blood; % eosinophils in blood; % eosinophils and myeloblasts in bone marrow; in addition to spleen size reduction of ≥ 50% by palpation and/ or ≥35% by imaging (if increased at baseline).
次要结局
- Median Progression-free survival (PFS)(3 years)
- Time to response (TTR)(3 years)
- Adverse events(3 years)
- Proportion of subjects who become corticosteroid-independent(3 years)
- Proportion of patients who reduce corticosteroid dose by >= 50% (including patients who become corticosteroid-independent)(3 years)
- Duration of response (DoR)(3 years)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
2 期
Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell TransplantRecurrent Diffuse Large B-Cell LymphomaRecurrent Mature T- and NK-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Mature T-Cell and NK-Cell Non-Hodgkin LymphomaNCT01431209University of Nebraska71
招募中
2 期
Ruxolitinib in Thrombocythemia and Polycythemia VeraEssential ThrombocythemiaPolycythemia VeraNCT04644211Massachusetts General Hospital60
已完成
2 期
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple MyelomaMultiple MyelomaNCT00639002Incyte Corporation13
终止
2 期
Ruxolitinib In GvHDGraft vs Host DiseaseNCT02396628Prof. Dr. Nikolas von Bubnoff22
终止
3 期
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)COVID-19NCT04377620Incyte Corporation211